<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04476238</url>
  </required_header>
  <id_info>
    <org_study_id>2020-01026</org_study_id>
    <nct_id>NCT04476238</nct_id>
  </id_info>
  <brief_title>Inosine Energy Expenditure Study</brief_title>
  <acronym>InoBAT</acronym>
  <official_title>Randomized Cross-over Trial to Investigate the Effect of Inosine on Human Energy Expenditure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators want to test whether the intake of the nucleoside inosine increases the human
      energy expenditure. Inosine occurs as a metabolic intermediate in the human body and is
      sometimes taken as a dietary supplement by athletes.

      For this purpose, investigators will measure the basal metabolic rate by indirect
      calorimetry. Study participants will then take inosine dissolved in water or placebo and
      energy expenditure will be assessed again.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>REE after Inosine</measure>
    <time_frame>one hour after oral intake of inosine</time_frame>
    <description>resting energy expenditure (REE) after oral intake of two grams of inosine as compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in energy expenditure</measure>
    <time_frame>one hour after oral intake of inosine</time_frame>
    <description>- Difference in EE between baseline measurement and measurement one hour after administration of inosine or control, respectively, at each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Quotient</measure>
    <time_frame>one hour after oral intake of inosine</time_frame>
    <description>- Respiratory quotient (RQ) as an indicator of substrate oxidation one hour after oral intake of two grams of inosine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum inosine level</measure>
    <time_frame>0 hours, 1 hour, 2 hours</time_frame>
    <description>Serum inosine levels after ingestion of inosine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Inosine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 grams of inosine dissolved in 250 ml of tap water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>250 ml of tap water only</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inosine</intervention_name>
    <description>2 grams of inosine dissolved in 250 ml water taken by mouth</description>
    <arm_group_label>Inosine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>250 ml water taken by mouth</description>
    <arm_group_label>Water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers

          -  BMI between 18-27 kg/m2

          -  Age between 18 and 40 years

        Exclusion Criteria:

          -  Chronic concomitant disease states (e.g., renal failure, hepatic dysfunction,
             cardiovascular disease, diabetes mellitus),

          -  Known or suspected non-compliance, drug or alcohol abuse,

          -  Inability to follow the procedures of the study

          -  Participation in another study with investigational drug within the 30 days preceding
             and during the present study,

          -  Previous enrolment into the current study,

          -  Enrolment of the investigator, his/her family members, employees and other dependent
             persons,

          -  Thyroid disorders
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthias J Betz, MD</last_name>
    <phone>0041 61 265</phone>
    <phone_ext>2525</phone_ext>
    <email>Matthias.Betz@usb.ch</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Energy expenditure</keyword>
  <keyword>metabolism</keyword>
  <keyword>inosine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

